

biomolecule which includes at least one biopolymer marker including the sequence identified as

SEQ ID NO: 1 or an analyte thereof related to said disease state; and

means for determining binding between said biochemical material and said biomolecule;

whereby at least one analysis to determine a presence of a marker, analyte thereof, or a

biochemical material specific thereto, is carried out on a sample.

---

BB Sub Sulf 25. The kit of claim 18, wherein said marker includes the sequence identified as SEQ ID

NO: 1 or at least one analyte thereof and said biochemical material is at least one monoclonal

antibody specific therefore.

---

BB Sub Sulf 29. Polyclonal antibodies produced against the marker having a sequence identified as

SEQ ID NO: 1 in at least one animal host.

BB Sub Sulf 30. An antibody that specifically binds a biopolymer including the marker sequence

identified as SEQ ID NO: 1 or at least one analyte thereof.

---

BB Sub Sulf 33. A process for identifying therapeutic avenues related to a disease state comprising:

conducting an analysis as provided by the kit of claim 18; and

interacting with a biopolymer including the sequence identified as SEQ ID NO: 1 or at

least one analyte thereof;

whereby therapeutic avenues are developed.

*SWT*

*SD*

34. The process for identifying therapeutic avenues related to a disease state in accordance with claim 33, wherein said therapeutic avenues regulate the presence or absence of the biopolymer including the sequence identified as SEQ ID NO: 1 or at least one analyte thereof.

*BG*

*CJ*

35. A process for regulating a disease state by controlling the presence or absence of a biopolymer including the sequence identified as SEQ ID NO: 1 or at least one analyte thereof.

---

REMARKS

The foregoing Supplemental Preliminary Amendment is made in conjunction with the simultaneous entry of the response to the Notice to Comply with Requirements for Patent Applications, filed concurrently herewith, so as to further bring this application into conformance with Rules 37 CFR §1.821 - 1.825. No new matter is added. Examination on the merits is respectfully requested.